Excerpt from Kallmann Syndrome and Idiopathic Hypogonadotropic HypogonadismSynonyms, Key Words, and Related Terms: Kallmann syndrome, KS, idiopathic hypogonadotropic hypogonadism, IHH, De Morsier syndrome, olfactogenital dysplasia, hypothalamic amenorrhea, acquired idiopathic hypogonadotropic hypogonadism, gonadotropin-releasing hormone deficiency, GnRH deficiency, DAX1, fertile eunuch syndrome, classic KS, classic IHH, congenital KS, congenital IHH, adult-onset IHH, acquired IHH, hypothalamic amenorrhea, X-linked KS, gonadal steroid replacement therapy, anosmia, hyposmia Please click here to view the full topic text: Kallmann Syndrome and Idiopathic Hypogonadotropic HypogonadismBackgroundClassic Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) are rare genetic conditions that encompass the spectrum of isolated hypogonadotropic hypogonadism. Most patients have a gonadotropin-releasing hormone (GnRH) deficiency, as suggested by their response to pulsatile GnRH therapy. Hypothalamic-pituitary function is otherwise normal in most patients, and hypothalamic-pituitary imaging reveals no space-occupying lesions. By definition, either anosmia (lack of sense of smell) or severe hyposmia is present in KS patients, in contrast to patients with IHH, whose sense of smell is normal. PathophysiologyDeficient hypothalamic GnRH secretion underlies the markedly abnormal gonadotropin secretion patterns in most patients with KS or IHH. The result is hypogonadism; infertility; and absent, incomplete, or partial pubertal maturation. Some of the genes involved in the pathogeneses of KS and IHH have been cloned. Mutations of the KAL gene, which encodes a putative neural cell adhesion molecule, have been described in several patients with X-linked KS. In these patients, both GnRH deficiency and anosmia are believed to be secondary to abnormalities of neuronal migration during development. Loss-of-function mutations of the gene encoding fibroblast growth factor receptor 1 (FGFR1) have recently been described in patients with autosomal dominant KS. Mutations of the DAX1 gene, which encodes a nuclear transcription factor, lead to X-linked IHH associated with adrenal hypoplasia congenita (AHC). Mutations of genes encoding either leptin or the leptin receptor underlie isolated cases of autosomally transmitted IHH associated with early-onset obesity. Mutations of the GnRH receptor gene leading to GnRH resistance and autosomally transmitted hypogonadotropic hypogonadism have been described. Rarely, hypogonadotropic hypogonadism occurs as a result of isolated follicle-stimulating hormone (FSH) deficiency due to homozygous mutations in the FSH beta subunit gene. In 1 patient, isolated bioinactive luteinizing hormone (LH) was present because of a homozygous mutation in the LH beta subunit gene, which led to hypogonadotropic hypogonadism. In another patient, a mutation in the prohormone convertase gene (PC1) led to hypogonadotropic hypogonadism, in addition to extreme obesity, hypocortisolemia, and deficient conversion of proinsulin to insulin. Homozygous mutations in GPR54, a gene encoding a G protein–coupled receptor, have recently been reported as a cause of hypogonadotropic hypogonadism. The physiologic role of kisspeptin-54, the endogenous neuropeptide agonist for this receptor, is under investigation. In addition, heterozygous missense mutations of the human nasal embryonic LHRH factor (NELF) gene may be associated with hypogonadotropic hypogonadism. FrequencyInternationalThe prevalence of IHH was approximately 1 in 10,000 men in a study of French conscripts (Fromantin, 1973). A study of Sardinian military recruits reports the prevalence of hypogonadism associated with anosmia (KS) as 1 in 86,000 men (Filippi, 1986). Methodological limitations of case ascertainment by medical record review should be kept in mind when interpreting these findings. Mortality/Morbidity
Sex
Age
Please click here to view the full topic text: Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism |
About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|||
|
Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |